Print this page    •   Back to Web version of article

The Body Covers: The 12th International AIDS Conference

Poster Session 32172: Protease Inhibitor-Associated Hyperglycemia: Results of Switching from Indinavir to Nelfinavir

Coverage provided by Michael Giordano, M.D.

July 1, 1998

Hyperglycemia and the development of diabetes mellitus is an emerging side effect of all of the protease inhibitors currently in use. As of November 1997, the FDA has received reports of 234 PI-related hyperglycemia from among the tens of thousands of people receiving PI therapy.

This small observational study looked at 8 men (mean age 47) receiving indinavir (IDV) therapy who developed new-onset hyperglycemia, and then switched to nelfinavir (NFV). None of these patients were receiving any other drugs known to affect glucose tolerance (such as growth hormone, pentamidine, and others), but four of the eight (50%) had a family history of adult-onset diabetes.

Two patients stopped indinavir immediately after developing hyperglycemia, with one being treated with hyperglycemia drugs for four days, after which the hyperglycemia resolved. The other was not treated, and his hyperglycemia resolved over a period of a few weeks. Six patients switched directly from indinavir to nelfinavir; three of them have had no significant improvement in their hyperglycemia.

In terms of the impact of the switch to nelfinavir on viral load, results were decidedly mixed. Four of the eight patients were undetectable at the time treatment was changed; two of them experienced viral rebound after switching to nelfinavir, but they had not switched their underlying RTI treatment at the time of the change. Both patients did manage to get to undetectable again after switching their nucleoside analogs treatment.

While it is difficult to draw firm conclusions from this small study, the researchers suggest that although NFV may have a lesser tendency to effect glucose metabolism than IDV, the occurrence of viral load rebound following the switch from IDV to NFV is cause for concern. When new treatment options are limited, they conclude, it may be preferable to continue IDV and treat the diabetes rather than switch to a new PI (or to a non-nucleoside reverse transcriptase regimen) and risk an increase in viral load.




This article was provided by TheBodyPRO.com. Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:
http://www.thebody.com/content/art14672.html

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.